Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC – Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 30th, there was short interest totaling 2,442 shares, a drop of 85.9% from the October 15th total of 17,259 shares. Based on an average trading volume of 35,837 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s shares are short sold.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded Frazier Life Sciences Acquisition Corp. II to a “hold” rating in a research report on Saturday, October 24th.
Get Our Latest Report on Frazier Life Sciences Acquisition Corp. II
Frazier Life Sciences Acquisition Corp. II Stock Down 0.4%
NASDAQ FLSC traded down $0.04 on Friday, hitting $10.10. 3,422 shares of the stock were exchanged, compared to its average volume of 30,243. Frazier Life Sciences Acquisition Corp. II has a 52-week low of $10.08 and a 52-week high of $10.63.
Insider Activity at Frazier Life Sciences Acquisition Corp. II
In related news, CEO Albert Cha purchased 300,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The stock was bought at an average price of $10.00 per share, for a total transaction of $3,000,000.00. Following the completion of the transaction, the chief executive officer owned 300,000 shares in the company, valued at approximately $3,000,000. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.
About Frazier Life Sciences Acquisition Corp. II
Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company (SPAC) formed to pursue a merger, asset acquisition, stock purchase, reorganization or similar business combination. Its stated focus is on businesses in the life sciences sector. As a SPAC, the company does not itself develop or sell medicines, medical devices or other products. Its role is to identify and combine with a target business, which would then operate as a public company. The company is associated with Frazier Life Sciences, the life sciences investment arm of Frazier Healthcare Partners.
See Also
- Five stocks we like better than Frazier Life Sciences Acquisition Corp. II
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Frazier Life Sciences Acquisition Corp. II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frazier Life Sciences Acquisition Corp. II and related companies with MarketBeat.com's FREE daily email newsletter.
